News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Genentech, Inc. (JOBS), Biogen Idec, Inc. (Massachusetts)'s Rituxan Meets Goal in Late Stage Leukemia Trial
October 7, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
SOUTH SAN FRANCISCO, Calif. -Genentech Inc. and Biogen Idec Inc. said Tuesday their cancer drug Rituxan slowed the progress of chronic lymphocytic leukemia in a late stage clinical trial, meeting its primary goal.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase III
MORE ON THIS TOPIC
Vaccines
CDC Highlights Efficacy of COVID-19 Shots in Kids Amid FDA Probe of Alleged Deaths
December 12, 2025
·
2 min read
·
Tristan Manalac
Parkinson’s disease
AC Immune’s Parkinson’s Immunotherapy Appears to Slow Disease Progression
December 11, 2025
·
1 min read
·
Annalee Armstrong
Obesity
Lilly’s Retatrutide Scores Triple Trial Triumph With 26% Weight Loss, But New Safety Signal Emerges
December 11, 2025
·
3 min read
·
Annalee Armstrong
Breast cancer
Pfizer Builds Case for Tukysa as ‘New Standard Regimen’ in First-Line Metastatic Breast Cancer
December 11, 2025
·
2 min read
·
Tristan Manalac
